Our results suggest that nuclear HSP110 expression in gastric cancer may be a new prognostic and drug sensitivity marker, and HSP110 may serve as a new molecular therapeutic target for the treatment of refractory gastric cancer. This evidence concerns the gene HSPH1 and gastric cancer.